13F filer · CIK 1907884
Kynam Capital Management, LP
PRINCETON, NJ · filing since Q4 2021 · last filing Aug 14, 2026
Reported value
$1.8B
+$188.3M vs prior
Positions
32
New / sold out
5 / 12
Added / reduced
12 / 6
Turnover
15.7%
buys $269.5M · sells $302.9M
Top-10 weight
72.7%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | VIRIDIAN THERAPEUTICS INC | +4,112,225 | +175.6% | +$75.5M |
| Added | LEGEND BIOTECH CORP | +1,424,910 | +90.4% | +$41.2M |
| Added | RELAY THERAPEUTICS INC | +1,875,741 | +131.7% | +$35.1M |
| Added | CYTOMX THERAPEUTICS INC. | +6,690,000 | +44.6% | +$25.1M |
| Added | TRAVERE THERAPEUTICS INC | +430,982 | +27.5% | +$24.5M |
| New | SUMMIT THERAPEUTICS INC | +1,200,000 | – | +$17.5M |
| Added | IMMUNOCORE HLDGS PLC | +490,063 | +55.4% | +$15.6M |
| New | INSMED INC | +100,000 | – | +$10.7M |
| Added | UROGEN PHARMA LTD | +186,814 | +8.3% | +$6.9M |
| New | PARABILIS MEDICINES INC | +250,000 | – | +$6.8M |
7 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | KALVISTA PHARMACEUTICALS INC | -1,820,954 | -100.0% | $-36.7M |
| Sold out | APELLIS PHARMACEUTICALS INC | -825,000 | -100.0% | $-33.2M |
| Reduced | BIOCRYST PHARMACEUTICALS INC | -3,158,135 | -55.6% | $-31.6M |
| Reduced | BEAM THERAPEUTICS INC | -841,393 | -22.9% | $-28.9M |
| Sold out | TRAVERE THERAPEUTICS INCCALL | -800,000 | -100.0% | $-23.8M |
| Reduced | VERA THERAPEUTICS INC | -508,165 | -15.0% | $-21.8M |
| Sold out | REVOLUTION MEDICINES INCPUT | -207,500 | -100.0% | $-20.2M |
| Reduced | CELLDEX THERAPEUTICS INC NEW | -517,659 | -8.9% | $-19.3M |
| Sold out | SOLENO THERAPEUTICS INC | -560,000 | -100.0% | $-18.7M |
| Sold out | EVOMMUNE INC | -625,496 | -100.0% | $-14.4M |
8 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | CELLDEX THERAPEUTICS INC NEWCOM NEW | 5,322,908 | $198.1M | 10.95% |
| 2 | SYNDAX PHARMACEUTICALS INCCOM | 8,050,959 | $176.0M | 9.73% |
| 3 | VAXCYTE INCCOM | 2,922,335 | $169.9M | 9.39% |
| 4 | COGENT BIOSCIENCES INCCOM | 3,667,097 | $141.9M | 7.84% |
| 5 | VERA THERAPEUTICS INCCL A | 2,890,059 | $124.0M | 6.85% |
| 6 | VIRIDIAN THERAPEUTICS INCCOM | 6,453,877 | $118.6M | 6.55% |
| 7 | TRAVERE THERAPEUTICS INCCOM | 2,000,000 | $113.6M | 6.28% |
| 8 | BEAM THERAPEUTICS INCCOM | 2,840,792 | $97.5M | 5.39% |
| 9 | UROGEN PHARMA LTDCOM | 2,434,207 | $89.6M | 4.95% |
| 10 | LEGEND BIOTECH CORPSPONSORED ADS | 3,001,205 | $86.7M | 4.79% |
22 more rows. Subscribe for $29/month to see every row, download the data and use the API.